These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10587263)

  • 21. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
    Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
    J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.
    Hay JK; Larson VS
    Can Vet J; 2019 Dec; 60(12):1326-1330. PubMed ID: 31814640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of ifosfamide for treatment of various canine neoplasms.
    Rassnick KM; Frimberger AE; Wood CA; Williams LE; Cotter SM; Moore AS
    J Vet Intern Med; 2000; 14(3):271-6. PubMed ID: 10830540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
    Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
    J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of canine mast cell tumors to treatment with oral prednisone.
    McCaw DL; Miller MA; Ogilvie GK; Withrow SJ; Brewer WG; Klein MK; Bell FW; Anderson SK
    J Vet Intern Med; 1994; 8(6):406-8. PubMed ID: 7884726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
    Fewer D; Wilson CB; Boldrey EB; Enot JK
    Cancer Chemother Rep; 1972 Jun; 56(3):421-7. PubMed ID: 19051504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH; Mauldin EA; Vail DM
    J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
    Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
    J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
    Hosoya K; Lord LK; Lara-Garcia A; Kisseberth WC; London CA; Couto CG
    Vet Comp Oncol; 2009 Dec; 7(4):244-55. PubMed ID: 19891695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).
    Gieger TL; Théon AP; Werner JA; McEntee MC; Rassnick KM; DeCock HE
    J Vet Intern Med; 2003; 17(5):687-92. PubMed ID: 14529136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
    Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
    J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple cutaneous histiocytomas treated with lomustine in a dog.
    Maina E; Colombo S; Stefanello D
    Vet Dermatol; 2014 Dec; 25(6):559-62, e98-9. PubMed ID: 24963782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
    Musser ML; Quinn HT; Chretin JD
    J Feline Med Surg; 2012 Dec; 14(12):871-5. PubMed ID: 22772480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
    Intile JL; Rassnick KM; Bailey DB; Al-Sarraf R; Chretin JD; Balkman CE; Flory AB; Kiselow MA; Wakshlag JJ
    Vet Comp Oncol; 2009 Mar; 7(1):69-77. PubMed ID: 19222832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.
    Doyle AJ; MacDonald VS; Bourque A
    Can Vet J; 2013 Dec; 54(12):1137-41. PubMed ID: 24293673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.